Mller TD, Finan B, Bloom SR, DAlessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschp MH
Greenwald, R.A.) 217220 (CRC Press, Boca Raton, Florida, 1985)
"The consistency that I'm hearing from all across patient groups is gain of control, whereas previously, there was a loss of control," Gitanjali Srivastava, MD, an internist and director of the obesity medicine program at Vanderbilt University Medical Center in Nashville, Tennessee, told MedPage Today
The only difference is the FDA approval indicationMounjaro is approved for type 2 diabetes while Zepbound is approved for weight loss